425: ReShape Lifesciences Announces Merger with Vyome Therapeutics and Asset Sale to Biorad

ReShape Lifesciences is merging with Vyome Therapeutics, selling assets to Biorad for $5.16 million, and focusing on the Lap-Band 2.0 FLEX launch amid GLP-1 market impact.

Summary

• ReShape Lifesciences held its second-quarter 2024 earnings call on August 15, 2024.
• The company is merging with Vyome Therapeutics and selling assets to Biorad.
• ReShape is focusing on stabilizing revenues and reducing costs, achieving a 45% reduction in operating expenses for the first half of 2024 compared to the previous year.
• The company is commercially launching the redesigned Lap-Band 2.0 FLEX, with a widespread launch anticipated after the limited market release.
• Biorad will purchase assets, including the Lap-Band system, Obalon Gastric Balloon System, and the Diabetes Bloc-Stim Neuromodulation system, for $5.16 million in cash.
• The merger with Vyome Therapeutics will result in a new entity called Vyome Holdings, Inc., with the stock ticker symbol HIND.
• Vyome Therapeutics is a clinical-stage company focused on treating immuno-inflammatory diseases.
• Certain Vyome stockholders have committed to a minimum $7.3 million private placement in the combined company.
• ReShape's revenue for the quarter was $2 million, a decrease of $300,000 compared to the same period in 2023.
• Revenue for the six months ended June 30, 2024, was $3.9 million, a decrease of $600,000 compared to the same period in 2023.
• The company's gross profit for the quarter was $1.1 million, slightly below $1.2 million for the same period in 2023.
• The gross profit as a percentage of total revenue for the quarter increased to 58% compared to 53% for the same period in 2023.
• The adjusted EBITDA loss was $1.9 million for the quarter, compared to a loss of $3.7 million in the same period last year.
• The company ended the quarter with net working capital of approximately $2.9 million, including $1.2 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While revenue is down, cost reductions and the merger with Vyome present potential for future growth. The positive feedback on the Lap-Band 2.0 FLEX and the commitment of capital from Vyome stockholders are also encouraging.

Positives

• Merger with Vyome Therapeutics provides a new strategic direction and potential for growth in immuno-inflammatory diseases.
• Asset sale to Biorad generates $5.16 million in cash to cover transaction costs.
• Significant reduction in operating expenses (45%) improves financial stability.
• Increased gross profit margin (58%) indicates improved efficiency.
• Positive initial feedback on the Lap-Band 2.0 FLEX suggests a successful product launch.
• Commitment of $7.3 million private placement from Vyome stockholders provides additional capital.
• The company has no debt on its balance sheet.

Negatives

• Revenue decreased by $300,000 for the quarter and $600,000 for the six-month period due to the impact of GLP-1 pharmaceuticals.
• Gross profit was slightly below the same period in the previous year.
• The company paused clinical trial work to preserve cash.

Risks

• The widespread adoption of GLP-1 receptor agonists may continue to negatively impact sales of the Lap-Band system.
• The merger with Vyome Therapeutics may not be completed successfully.
• The company may be unable to obtain stockholder approval for the proposed merger and asset sale.
• The company may face unexpected costs, liabilities, or delays related to the merger and asset sale.
• The company's business may suffer as a result of uncertainty surrounding the merger and asset sale.
• The company may be adversely affected by economic, business, and/or competitive factors.

Future Outlook

The company anticipates a widespread commercial launch of the Lap-Band 2.0 FLEX. Vyome expects to self-fund into the second half of 2025 based on anticipated cash flow projections and plans to deploy capital to unlock value in its pipeline of immuno-inflammatory assets.

Management Comments

• Paul Hickey: 'We feel we are successfully maximizing stockholder value and earnings potential.'
• Paul Hickey: 'We believe that the market opportunity for the Lap-Band will increase over time, especially with the newly launched next-generation Lap-Band 2.0 FLEX.'
• Krishna Gupta: 'We are excited about using our new public platform to strengthen our existing assets and unlock key value milestones from our pipeline, leveraging the world-class Indian innovation corridor and the US market.'
• Krishna Gupta: 'We feel like we are very aligned with ReShapes shareholder expectations for a disciplined and focused business model executed flawlessly to help ensure we maximize shareholder value.'

Industry Context

The announcement addresses the impact of GLP-1 receptor agonists on the obesity market and positions the Lap-Band 2.0 FLEX as a long-term solution. The merger with Vyome Therapeutics reflects a strategic shift towards the immuno-inflammation sector, aligning with current trends in pharmaceutical development.

Comparison to Industry Standards

• The company's focus on cost reduction and improved gross margins aligns with industry best practices for companies facing revenue challenges.
• The merger with Vyome Therapeutics is similar to other strategic acquisitions in the pharmaceutical industry aimed at diversifying product pipelines and accessing new markets.
• The asset sale to Biorad is a common strategy for companies to streamline operations and focus on core competencies.
• Companies like Apollo Endosurgery, which also offer bariatric surgery solutions, are direct competitors in the obesity market.
• The focus on the Indian innovation corridor is similar to strategies employed by other companies seeking to leverage cost-effective research and development capabilities.

Stakeholder Impact

• Shareholders will be impacted by the merger with Vyome Therapeutics and the potential for future growth.
• Employees may be affected by the reorganization and cost reduction efforts.
• Customers will benefit from the launch of the Lap-Band 2.0 FLEX.
• Suppliers may be impacted by the asset sale to Biorad.
• Creditors are not directly impacted as the company remains debt-free.

Next Steps

• File an S-4 registration statement, including the proxy statement related to the merger and asset purchase agreement.
• Hold a shareholder meeting for the approval of the transactions.
• Complete the merger with Vyome Therapeutics and the asset sale to Biorad.
• Commercially launch the Lap-Band 2.0 FLEX.
• Deploy capital raised through the private placement to advance Vyome's pipeline of immuno-inflammatory assets.

Key Dates

Keywords

Vyome Therapeutics, ReShape Lifesciences, Merger, Asset Sale, Biorad, Lap-Band, GLP-1, Obesity, Weight Loss, Financial Results, HIND, Immun-inflammatory